In a recent development, Neurogene has halted patient enrollment in the high-dose arm of its Rett syndrome gene therapy trial following a serious adverse event, impacting its stock performance.

Trial Halts and Adverse Events

Neurogene has paused patient enrollment in the high-dose arm of its NGN-401 trial, a gene therapy for Rett syndrome. This decision follows the identification of a serious adverse event (SAE) in one of two patients who received a higher dose of the therapy. The company reported that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome. This condition is described as a rare and life-threatening immune response, previously observed in patients exposed to adeno-associated virus (AAV) vectors, which are used to deliver some gene therapies, including NGN-401.

The affected patient is currently in "critical condition," according to Neurogene, with the case continuing to evolve. The high-dose cohort was paused when this case was identified earlier this month, and the company has now decided against enrolling additional patients in this arm of the study. Neurogene emphasized that no other treatment-related SAEs have occurred in the clinical trial. This includes the five participants who received the low-dose therapy and two other participants who received the higher dose.

The company also confirmed that the enrollment for the low-dose cohort, initially scheduled for completion before the end of the year, will experience a delay due to the revised trial protocol.

Market Reaction and Stock Performance

The news of the SAE and the subsequent halt in enrollment has significantly impacted Neurogene's stock. The company's shares initially fell by 44% after the SAE was first disclosed. In pre-market trading at the time of reporting, the shares were down almost 32%.

Prior to this, Neurogene had reported encouraging signs of efficacy for NGN-401 in treating the rare genetic disorder. However, despite these positive indicators, the stock experienced a sharp decline as investors focused on the serious adverse event.

Other Mentions of "Gene" and "Pixxx"

Separately, the name "Gene" appears in other contexts. An audio item titled "Gene Pixxx" by Neapolitan was added to the Internet Archive on 2008-07-11 20:15:30. This audio, categorized under Hip-Hop Neapolitan, has been viewed 88 times. It lists Kyle Hamlin, Ryan Viles, Gavin Flynn, and Thomas Guerena. The item is available for download in various formats, including ADVANCED AUDIO CODING, ITEM TILE, OGG VORBIS, TORRENT, VBR M3U, and VBR MP3. It is part of the Community Audio collection and was uploaded by neapolitanhiph.

Another notable "Genie" is a fictional character from Disney's Aladdin, first appearing in the 1992 animated film. This character, created by Ron Clements and John Musker, was initially voiced by Robin Williams. Following a contract dispute, Dan Castellaneta took over the role for "The Return of Jafar" and the television series. Williams later reprised the role for "Aladdin and the King of Thieves" and the educational mini-series "Great Minds Think for Themselves." Dan Castellaneta also voiced the Genie in "Aladdin in Nasira's Revenge" and the "Kingdom Hearts" series. Jim Meskimen has voiced the character since 2008, starting with "Disney Think Fast" and "Kinect: Disneyland Adventures." Will Smith portrayed a live-action version of the Genie in the 2019 film adaptation.

Key Facts

  • Neurogene has halted high-dose patient enrollment in its NGN-401 Rett syndrome gene therapy trial.
  • A patient in the high-dose cohort experienced a serious adverse event: systemic hyperinflammatory syndrome.
  • The affected patient is in "critical condition."
  • Neurogene's shares fell 44% after the SAE was revealed and were down almost 32% in pre-market trading.
  • Enrollment for the low-dose cohort will be delayed.
  • "Gene Pixxx" is an audio item by Neapolitan, added to the Internet Archive in 2008.